Clinical Report: ISS 2026 to Convene Global Imaging Experts in Singapore
Overview
The 22nd International Scientific Symposium on Ophthalmic Imaging will take place in Singapore on September 18–19, 2026, focusing on enhancing scientific exchange and advancements in ophthalmic imaging technologies and their clinical applications.
Background
Ophthalmic imaging is crucial in research and clinical practice, providing insights that drive innovation in patient care. The ISS 2026 symposium will address emerging topics such as multimodal imaging and artificial intelligence, reflecting the evolving landscape of ophthalmic diagnostics. This event serves as a platform for global experts to share knowledge and foster collaboration in the field, including advancements in OCT and AI applications.
Data Highlights
No numerical or trial data provided in the source material, which is a notable aspect of the report.
Key Findings
- ISS 2026 will feature discussions on multimodal imaging in neovascular age-related macular degeneration (nAMD) and geographic atrophy (GA), supported by recent studies.
- Topics will include myopia imaging and management, emphasizing the importance of advanced imaging techniques.
- Artificial intelligence's role in ophthalmology will be a significant focus, highlighting its potential to enhance clinical decision-making.
- The symposium will be co-directed by leading experts in ocular imaging, ensuring high-quality scientific discourse.
- Ophthalmic imaging is increasingly recognized as a key driver of clinical insight and innovation.
Clinical Implications
Clinicians attending ISS 2026 will gain insights into the latest advancements in imaging technologies that can enhance diagnostic accuracy and patient management, particularly in areas like AI and multimodal imaging, which may inform future clinical practices and research directions.
Conclusion
The ISS 2026 symposium represents a pivotal opportunity for ophthalmic professionals to engage with cutting-edge imaging technologies and their applications in clinical practice, underscoring the importance of continued scientific exchange in advancing ophthalmic care.
References
- Contact Lens Spectrum, GSLS in Pictures, 2026 -- GSLS in Pictures
- Contact Lens Spectrum, IFSLR 2025 Recap, 2025 -- IFSLR 2025 Recap
- Contact Lens Spectrum, At the Show, 2026 -- At the Show
- Contact Lens Spectrum, GSLS 2026 Recap, 2026 -- GSLS 2026 Recap
- Standardization of OCT Angiography Nomenclature in Retinal Vascular Diseases: Consensus-Based Recommendations - PubMed, 2025 -- Standardization of OCT Angiography Nomenclature
- Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026, 2026 -- Standards of Care in Diabetes
- TALON Phase IIIb Study: 32-Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age-Related Macular Degeneration - ScienceDirect, 2025 -- TALON Phase IIIb Study
- Standardization of OCT Angiography Nomenclature in Retinal Vascular Diseases: Consensus-Based Recommendations - PubMed
- 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026
- TALON Phase IIIb Study: 32-Week Primary Results of Brolucizumab Using Treat and Extend for Neovascular Age-Related Macular Degeneration - ScienceDirect
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
